Bio-Reference Laboratories (BRLI) 31.76 $BRLI
Becton, Dickinson Q3 Earnings Meet, Revenues Top Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 2:20PM CDT
For fiscal 2014, Becton, Dickinson and Company (BDX) reaffirmed its adjusted earnings per share guidance in the range of $6.22 to $6.25, which represents year-over-year growth of 7.0-7.5%.
DENTSPLY International Beats on Q2 Earnings, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:19PM CDT
For 2014, DENTSPLY International (XRAY) reaffirmed its adjusted-earnings per share guidance in the range of $2.47 to $2.55, reflecting a 5.1 to 8.5% rise over the prior year
Merit Medical Systems Slumps: MMSI Plunges 13.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:46AM CDT
Merit Medical Systems has seen flat earnings estimate revision for the current year along with a significant decline in its share price for the past few weeks
C R Bard Q2 Earnings and Revenues Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 3:20PM CDT
For 2014, CR Bard Inc. (BCR) increased its adjusted earnings per share guidance to the band of $8.25-$8.35 from the prior range of $8.20-$8.30.
CONMED Lags on Q2 Earnings & Revenues, Cuts View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:10PM CDT
CONMED Corporation (CNMD) lowered its adjusted earnings and revenue guidance for full-year 2014.
CONMED (CNMD) in Focus: Stock Tumbles 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:00AM CDT
CONMED stock fell over 9% last trading session, continuing its recent downuptrend
MWI Vet Upgraded to Strong Buy on Solid Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 5:10PM CDT
MWI Vet (MWIV) delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 3.4%.
Investors Are Shorting Bio-Reference Laboratories (BRLI) Stock: Is A Short Cover Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:10AM CDT
Investors Are Shorting Bio-Reference Laboratories (BRLI) Stock: Is A Short Cover Coming?
The Cooper Companies Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 12:50PM CDT
The Cooper Companies Inc. (COO) has been enjoying rising estimate revisions in the past 30 days with nine upward estimate revisions and no downward revision for 2014.
The Cooper Companies (COO) Jumps: Stock Rises 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:21AM CDT
The Cooper Companies Inc. (COO) was a big mover last session, as the company saw its shares rise by over 8% on the day.
STAAR Surgical Company Slumps: STAA Tanks 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:36AM CDT
STAAR Surgical Company has seen flat earnings estimate revision for the current year along with a significant decline in its share price for the last day
International Sales Continue to Boost Becton, Dickinson - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 5:15PM CDT
Becton, Dickinson (BDX) maintains its focus on geographical expansion into overseas markets, in particular, emerging markets
Antares Pharma (ATRS) Crumbles: Stock Falls by 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:39AM CDT
Antares Pharma has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the last day
Post Earnings Update: Bio-Reference Labs Has Sunk 9.9% Lower in Past 2 Weeks (BRLI)
Comtex SmarTrend(R) - Mon Jun 23, 7:06AM CDT
When Bio-Reference Labs (NASDAQ:BRLI) reported earnings 18 days ago on June 5th, 2014, analysts, on average, expected the company to report earnings of $0.32 on sales of $196.0 million. The company actually reported EPS of $0.37 on sales of $201.4 million, beating EPS estimates by $0.05 and beating revenue estimates by $5.4 million. Since the company's report, shares of Bio-Reference Labs have fallen from $32.74 to $29.49, representing a loss of 9.9% in the past 18 days.
Clinical Lab Services Market Report - Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Jun 17, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmgnn4/clinical_lab) has announced the addition of the "Clinical Lab Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)" report to their offering. The market for clinical lab services is dynamic. It is estimated that approximately 80% of physician's diagnoses are a result of laboratory tests, and a fair number of these tests are sent to clinical lab service providers. There is constant pressure to reduce healthcare spending, and that in turn is shifting healthcare utilization in favor of the laboratory. This has not escaped the attention of major competitors who operate in the industry, and those planning to enter. Clinical Laboratory Services (Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles), provides an in-depth market overview, a total market analysis, analysis by laboratory type, and by routine and specialty testing and a review of the latest trends driving growth. Revenues and forecasts, segment breakouts and market share presented are for the U.S. market, but international clinical lab service markets are estimated and forecasted in this report. Key market data provided includes: - Hospital, Physician and Independent Lab Statistics - Major Tests Performed by Clinical Lab Companies - Disease Incidence and Trends Driving Lab Business - Market Forecast to 2018 - Geographic Breakout of Clinical Lab Services Market (includes US, Europe Asia with specific breakouts for Germany, Japan, China, India and Brazil) - Market Breakdown by Lab Type (Hospital, Physician, Independent) - Market Breakdown by Test Type (Specialty, Routine) - US Market Share of Competitors - Competitive Analysis of Leading clinical Lab Providers A trend towards preventive and risk factor testing has been noted in several disciplines, particularly in the areas of oncology, endocrinology, and gynecology. Physicians in these areas are taking full advantage of testing for early detection and disease prevention. Some of the other issues and trends explored in this study include: - U.S. Demographics - Types of Specialty Tests - Growing Competition - Increasing Life Expectancy - Growing Incidence of Disease - New Product Offerings - Regulatory Environment - Insurance and Reimbursement - Payer Types - Developments in Personalized Medicine A competitive analysis of leading clinical laboratory providers includes: - Quest Diagnostics, Inc. - Laboratory Corporation of America (LabCorp) - Genomic Health - Genoptix, Inc. - Genzyme Corporation - DaVita - Clarient, Inc. - Spectra Laboratories - Bio-Reference Laboratories For more information visit http://www.researchandmarkets.com/research/bm...inical_lab
CR Bard Expands Share Repurchase Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 12:40PM CDT
In addition, CR Bard (BCR) raised the quarterly dividend on its stock by 5% to 22 cents per share.
Becton, Dickinson Unveils Blood Culture Instrument Connectivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 12:15PM CDT
Becton, Dickinson and Company (BDX) will now provide connectivity of the fully automated microbiology growth and detection technology BD BACTEC Blood Culture System with BD EpiCenter Microbiology Data Management System
Earnings Adjustment, Financial Results, Upcoming Conferences, and Product Shipments - Analyst Notes on Agilent, Bio-Reference, RadNet, Foundation Medicine and Fluidigm
PR Newswire - Tue Jun 10, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Agilent Technologies Inc. (NYSE: A), Bio-Reference Laboratories Inc. (NASDAQ: BRLI), RadNet, Inc. (NASDAQ: RDNT), Foundation Medicine, Inc. (NASDAQ: FMI) and Fluidigm Corporation (NASDAQ: FLDM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3529-100free.
Bioinformatics in IVD Testing
M2 - Fri Jun 06, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/79h69r/bioinformatics_in) has announced the addition of the "Bioinformatics in IVD Testing" report to their offering. Computer diagnostics could offer opportunity for clinical laboratory professionals to add value to clinicians in diagnosing diseases. IT companies in collaboration with test vendors are developing computer software that complements the skills of human test interpretation. This report, Bioinformatics in IVD Testing looks at the various IVD market segments where bionformatics is expected to have the most impact. Bioinformatics-based testing has made a huge contribution to cancer diagnosis and therapy management. In infectious disease diagnostics it allows the detection of difficult to culture pathogenic bacteria or viruses and to uncover the epidemiology of infections. The bioinformatic analysis of mutations of known human genes is used to diagnose common disorders, inherited diseases, or different types of cancer and can indicate the prognosis of malignant diseases. What developments are driving this trend? What are labs and providers doing to incorporate these products into practice? And how are payors and regulators reacting? Who is partnering with who to deliver a solid combination product? This report delves into these issues and provides an excellent round-up of the current status of bioinformatics in the IVD industry. As part of its coverage, the report provides information on the following developments: - Selected Diagnostic Tests That Incorporate Bioinformatics - Selected Multiplexed Tissue-Based Cancer Tests - Selected Histology Analyses Software Tools - Selected Blood-Based Cancer Biomarker Tests That Use Software Analysis Tools - Selected Innovations in Bioinformatic-Based Tests For CVD - Selected Chronic Diseases Tests With Integrated Bioinformatics - Selected Innovations in Bioinformatic-Based Tests For Psychiatric Disorders - Selected Systems For Bioinformatics-Based Infectious Disease Testing - Selected Next Generation Sequencing Platforms The report looks at the bioinformatics-based product offerings and developments of the following companies, among others: - Abbott - Cannon - RocheAffymetrix Inc. - AssureRx Health, Inc. - Genomic Health, Inc. - Bio-Reference Laboratories, Inc. (BRLI) - Dako A/S - Siemens - Thermo Fisher - Gen-Probe - Medtronic Inc. - PerkinElmer, Inc. - Prometheus Labs - QIAGEN N.V. - Quest In addition to surveying the many uses for bioinformatics in IVD, the report provides 2012 market estimates for the following IVD market segments: - Histology/Cytology - Immunoassays - Molecular Assays - Mass Spec Clinical Tests and Services - Molecular Pharmacodiagnostics - Tissue Arrays - Circulating Tumor Cells For more information visit http://www.researchandmarkets.com/research/79...rmatics_in
Bio-Reference Laboratories (BRLI) Catches Eye: Stock Soars 22.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 8:25AM CDT
Bio-Reference Laboratories (BRLI) was a big mover last session, with shares rising over 22% on the day.
Becton, Dickinson Q3 Earnings Meet, Revenues Top Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 2:20PM CDT
For fiscal 2014, Becton, Dickinson and Company (BDX) reaffirmed its adjusted earnings per share guidance in the range of $6.22 to $6.25, which represents year-over-year growth of 7.0-7.5%.
DENTSPLY International Beats on Q2 Earnings, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:19PM CDT
For 2014, DENTSPLY International (XRAY) reaffirmed its adjusted-earnings per share guidance in the range of $2.47 to $2.55, reflecting a 5.1 to 8.5% rise over the prior year
Merit Medical Systems Slumps: MMSI Plunges 13.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:46AM CDT
Merit Medical Systems has seen flat earnings estimate revision for the current year along with a significant decline in its share price for the past few weeks
C R Bard Q2 Earnings and Revenues Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 3:20PM CDT
For 2014, CR Bard Inc. (BCR) increased its adjusted earnings per share guidance to the band of $8.25-$8.35 from the prior range of $8.20-$8.30.
CONMED Lags on Q2 Earnings & Revenues, Cuts View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:10PM CDT
CONMED Corporation (CNMD) lowered its adjusted earnings and revenue guidance for full-year 2014.
CONMED (CNMD) in Focus: Stock Tumbles 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:00AM CDT
CONMED stock fell over 9% last trading session, continuing its recent downuptrend
MWI Vet Upgraded to Strong Buy on Solid Fundamentals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 5:10PM CDT
MWI Vet (MWIV) delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 3.4%.
Investors Are Shorting Bio-Reference Laboratories (BRLI) Stock: Is A Short Cover Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:10AM CDT
Investors Are Shorting Bio-Reference Laboratories (BRLI) Stock: Is A Short Cover Coming?
The Cooper Companies Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 12:50PM CDT
The Cooper Companies Inc. (COO) has been enjoying rising estimate revisions in the past 30 days with nine upward estimate revisions and no downward revision for 2014.
The Cooper Companies (COO) Jumps: Stock Rises 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:21AM CDT
The Cooper Companies Inc. (COO) was a big mover last session, as the company saw its shares rise by over 8% on the day.
STAAR Surgical Company Slumps: STAA Tanks 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:36AM CDT
STAAR Surgical Company has seen flat earnings estimate revision for the current year along with a significant decline in its share price for the last day
International Sales Continue to Boost Becton, Dickinson - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 5:15PM CDT
Becton, Dickinson (BDX) maintains its focus on geographical expansion into overseas markets, in particular, emerging markets
Antares Pharma (ATRS) Crumbles: Stock Falls by 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:39AM CDT
Antares Pharma has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the last day
Post Earnings Update: Bio-Reference Labs Has Sunk 9.9% Lower in Past 2 Weeks (BRLI)
Comtex SmarTrend(R) - Mon Jun 23, 7:06AM CDT
When Bio-Reference Labs (NASDAQ:BRLI) reported earnings 18 days ago on June 5th, 2014, analysts, on average, expected the company to report earnings of $0.32 on sales of $196.0 million. The company actually reported EPS of $0.37 on sales of $201.4 million, beating EPS estimates by $0.05 and beating revenue estimates by $5.4 million. Since the company's report, shares of Bio-Reference Labs have fallen from $32.74 to $29.49, representing a loss of 9.9% in the past 18 days.
Clinical Lab Services Market Report - Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Jun 17, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmgnn4/clinical_lab) has announced the addition of the "Clinical Lab Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)" report to their offering. The market for clinical lab services is dynamic. It is estimated that approximately 80% of physician's diagnoses are a result of laboratory tests, and a fair number of these tests are sent to clinical lab service providers. There is constant pressure to reduce healthcare spending, and that in turn is shifting healthcare utilization in favor of the laboratory. This has not escaped the attention of major competitors who operate in the industry, and those planning to enter. Clinical Laboratory Services (Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles), provides an in-depth market overview, a total market analysis, analysis by laboratory type, and by routine and specialty testing and a review of the latest trends driving growth. Revenues and forecasts, segment breakouts and market share presented are for the U.S. market, but international clinical lab service markets are estimated and forecasted in this report. Key market data provided includes: - Hospital, Physician and Independent Lab Statistics - Major Tests Performed by Clinical Lab Companies - Disease Incidence and Trends Driving Lab Business - Market Forecast to 2018 - Geographic Breakout of Clinical Lab Services Market (includes US, Europe Asia with specific breakouts for Germany, Japan, China, India and Brazil) - Market Breakdown by Lab Type (Hospital, Physician, Independent) - Market Breakdown by Test Type (Specialty, Routine) - US Market Share of Competitors - Competitive Analysis of Leading clinical Lab Providers A trend towards preventive and risk factor testing has been noted in several disciplines, particularly in the areas of oncology, endocrinology, and gynecology. Physicians in these areas are taking full advantage of testing for early detection and disease prevention. Some of the other issues and trends explored in this study include: - U.S. Demographics - Types of Specialty Tests - Growing Competition - Increasing Life Expectancy - Growing Incidence of Disease - New Product Offerings - Regulatory Environment - Insurance and Reimbursement - Payer Types - Developments in Personalized Medicine A competitive analysis of leading clinical laboratory providers includes: - Quest Diagnostics, Inc. - Laboratory Corporation of America (LabCorp) - Genomic Health - Genoptix, Inc. - Genzyme Corporation - DaVita - Clarient, Inc. - Spectra Laboratories - Bio-Reference Laboratories For more information visit http://www.researchandmarkets.com/research/bm...inical_lab
CR Bard Expands Share Repurchase Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 12:40PM CDT
In addition, CR Bard (BCR) raised the quarterly dividend on its stock by 5% to 22 cents per share.
Becton, Dickinson Unveils Blood Culture Instrument Connectivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 12:15PM CDT
Becton, Dickinson and Company (BDX) will now provide connectivity of the fully automated microbiology growth and detection technology BD BACTEC Blood Culture System with BD EpiCenter Microbiology Data Management System
Earnings Adjustment, Financial Results, Upcoming Conferences, and Product Shipments - Analyst Notes on Agilent, Bio-Reference, RadNet, Foundation Medicine and Fluidigm
PR Newswire - Tue Jun 10, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Agilent Technologies Inc. (NYSE: A), Bio-Reference Laboratories Inc. (NASDAQ: BRLI), RadNet, Inc. (NASDAQ: RDNT), Foundation Medicine, Inc. (NASDAQ: FMI) and Fluidigm Corporation (NASDAQ: FLDM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3529-100free.
Bioinformatics in IVD Testing
M2 - Fri Jun 06, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/79h69r/bioinformatics_in) has announced the addition of the "Bioinformatics in IVD Testing" report to their offering. Computer diagnostics could offer opportunity for clinical laboratory professionals to add value to clinicians in diagnosing diseases. IT companies in collaboration with test vendors are developing computer software that complements the skills of human test interpretation. This report, Bioinformatics in IVD Testing looks at the various IVD market segments where bionformatics is expected to have the most impact. Bioinformatics-based testing has made a huge contribution to cancer diagnosis and therapy management. In infectious disease diagnostics it allows the detection of difficult to culture pathogenic bacteria or viruses and to uncover the epidemiology of infections. The bioinformatic analysis of mutations of known human genes is used to diagnose common disorders, inherited diseases, or different types of cancer and can indicate the prognosis of malignant diseases. What developments are driving this trend? What are labs and providers doing to incorporate these products into practice? And how are payors and regulators reacting? Who is partnering with who to deliver a solid combination product? This report delves into these issues and provides an excellent round-up of the current status of bioinformatics in the IVD industry. As part of its coverage, the report provides information on the following developments: - Selected Diagnostic Tests That Incorporate Bioinformatics - Selected Multiplexed Tissue-Based Cancer Tests - Selected Histology Analyses Software Tools - Selected Blood-Based Cancer Biomarker Tests That Use Software Analysis Tools - Selected Innovations in Bioinformatic-Based Tests For CVD - Selected Chronic Diseases Tests With Integrated Bioinformatics - Selected Innovations in Bioinformatic-Based Tests For Psychiatric Disorders - Selected Systems For Bioinformatics-Based Infectious Disease Testing - Selected Next Generation Sequencing Platforms The report looks at the bioinformatics-based product offerings and developments of the following companies, among others: - Abbott - Cannon - RocheAffymetrix Inc. - AssureRx Health, Inc. - Genomic Health, Inc. - Bio-Reference Laboratories, Inc. (BRLI) - Dako A/S - Siemens - Thermo Fisher - Gen-Probe - Medtronic Inc. - PerkinElmer, Inc. - Prometheus Labs - QIAGEN N.V. - Quest In addition to surveying the many uses for bioinformatics in IVD, the report provides 2012 market estimates for the following IVD market segments: - Histology/Cytology - Immunoassays - Molecular Assays - Mass Spec Clinical Tests and Services - Molecular Pharmacodiagnostics - Tissue Arrays - Circulating Tumor Cells For more information visit http://www.researchandmarkets.com/research/79...rmatics_in
Bio-Reference Laboratories (BRLI) Catches Eye: Stock Soars 22.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 8:25AM CDT
Bio-Reference Laboratories (BRLI) was a big mover last session, with shares rising over 22% on the day.
